161 related articles for article (PubMed ID: 30345557)
1. Construction of a Novel Bispecific Antibody to Enhance Antitumor Activity against Lung Cancer.
Yin W; Zhu J; Gonzalez-Rivas D; Okumura M; Rocco G; Pass H; Jiang G; Yang Y
Adv Mater; 2018 Dec; 30(51):e1805437. PubMed ID: 30345557
[TBL] [Abstract][Full Text] [Related]
2. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
Mazor Y; Sachsenmeier KF; Yang C; Hansen A; Filderman J; Mulgrew K; Wu H; Dall'Acqua WF
Sci Rep; 2017 Jan; 7():40098. PubMed ID: 28067257
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
6. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
7. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
[TBL] [Abstract][Full Text] [Related]
8. Chemical generation of bispecific antibodies.
Doppalapudi VR; Huang J; Liu D; Jin P; Liu B; Li L; Desharnais J; Hagen C; Levin NJ; Shields MJ; Parish M; Murphy RE; Del Rosario J; Oates BD; Lai JY; Matin MJ; Ainekulu Z; Bhat A; Bradshaw CW; Woodnutt G; Lerner RA; Lappe RW
Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22611-6. PubMed ID: 21149738
[TBL] [Abstract][Full Text] [Related]
9. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
10. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.
Cao Y; Axup JY; Ma JS; Wang RE; Choi S; Tardif V; Lim RK; Pugh HM; Lawson BR; Welzel G; Kazane SA; Sun Y; Tian F; Srinagesh S; Javahishvili T; Schultz PG; Kim CH
Angew Chem Int Ed Engl; 2015 Jun; 54(24):7022-7. PubMed ID: 25919418
[TBL] [Abstract][Full Text] [Related]
11. p95HER2-T cell bispecific antibody for breast cancer treatment.
Rius Ruiz I; Vicario R; Morancho B; Morales CB; Arenas EJ; Herter S; Freimoser-Grundschober A; Somandin J; Sam J; Ast O; Barriocanal ÁM; Luque A; Escorihuela M; Varela I; Cuartas I; Nuciforo P; Fasani R; Peg V; Rubio I; Cortés J; Serra V; Escriva-de-Romani S; Sperinde J; Chenna A; Huang W; Winslow J; Albanell J; Seoane J; Scaltriti M; Baselga J; Tabernero J; Umana P; Bacac M; Saura C; Klein C; Arribas J
Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282693
[TBL] [Abstract][Full Text] [Related]
12. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.
Shalaby MR; Carter P; Maneval D; Giltinan D; Kotts C
Clin Immunol Immunopathol; 1995 Feb; 74(2):185-92. PubMed ID: 7828373
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
Kou G; Shi J; Chen L; Zhang D; Hou S; Zhao L; Fang C; Zheng L; Zhang X; Liang P; Zhang X; Li B; Guo Y
Cancer Lett; 2010 Dec; 299(2):130-6. PubMed ID: 20826049
[TBL] [Abstract][Full Text] [Related]
14. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Deng W; Liu J; Pan H; Li L; Zhou C; Wang X; Shu R; Dong B; Cao D; Li Q; Wang Z
J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
[TBL] [Abstract][Full Text] [Related]
15. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
[TBL] [Abstract][Full Text] [Related]
16. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects
Mohammadi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Arjmand M; Bahadori T; Judaki MA; Shiravi F; Zare HA; Haghighat FN; Mobini M; Amiri MM; Shokri F
Front Immunol; 2020; 11():600883. PubMed ID: 33679691
[TBL] [Abstract][Full Text] [Related]
17. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
18. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
[TBL] [Abstract][Full Text] [Related]
19. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.
Ding L; Tian C; Feng S; Fida G; Zhang C; Ma Y; Ai G; Achilefu S; Gu Y
Theranostics; 2015; 5(4):378-98. PubMed ID: 25699098
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
